Journal of Nanoparticle Research ( IF 2.1 ) Pub Date : 2024-03-01 , DOI: 10.1007/s11051-024-05955-y
Dilpreet Singh
![]() |
Lung adenocarcinoma, representing a major fraction of non-small cell lung cancer cases, remains one of the most challenging malignancies to treat. Although advances in traditional therapeutics have been made, the recurrence and resistance associated with this subtype underscore the necessity for innovative treatments. siRNA therapies, with their ability to mediate targeted gene silencing, have emerged as promising candidates but face considerable barriers, such as systemic instability and potential off-target impacts. The recent advent of biomembrane-derived nanoplexes heralds a transformative approach to overcome these challenges. By employing cell membranes for encapsulation, these nanoplexes ensure enhanced siRNA protection, prolonged circulation, and targeted delivery to tumorous sites, capitalizing on the innate properties of the source cells. This review synthesizes current knowledge on biomembrane-derived nanoplexes, focusing on their formulation, mechanisms of action, and therapeutic efficacy in the context of lung adenocarcinoma. Preliminary findings underscore the significant potential of these nanoplexes, suggesting a paradigm shift in siRNA delivery strategies and offering hope for improved patient outcomes in lung adenocarcinoma treatments. The exploration of these novel nanoplexes not only paves the way for enhanced lung cancer therapy but also broadens the horizon for their application in other malignancies, driving the field of oncological nanomedicine toward unprecedented advancements.
中文翻译:

用于 SiRNA 的生物膜衍生纳米复合物 - 肺腺癌递送的先驱创新
肺腺癌占非小细胞肺癌病例的主要部分,仍然是最具挑战性的恶性肿瘤之一。尽管传统疗法已取得进展,但与该亚型相关的复发和耐药性强调了创新疗法的必要性。 siRNA 疗法具有介导靶向基因沉默的能力,已成为有前途的候选疗法,但面临相当大的障碍,例如系统不稳定和潜在的脱靶影响。最近生物膜衍生的纳米复合物的出现预示着克服这些挑战的变革性方法。通过采用细胞膜进行封装,这些纳米复合物利用源细胞的先天特性,确保增强的 siRNA 保护、延长循环时间并靶向递送至肿瘤部位。本综述综合了生物膜衍生纳米复合物的最新知识,重点关注其配方、作用机制和在肺腺癌中的治疗效果。初步研究结果强调了这些纳米复合物的巨大潜力,表明 siRNA 递送策略发生了范式转变,并为改善肺腺癌治疗中的患者预后带来了希望。对这些新型纳米复合物的探索不仅为增强肺癌治疗铺平了道路,而且还拓宽了它们在其他恶性肿瘤中的应用视野,推动肿瘤纳米医学领域取得前所未有的进步。